Nektar Therapeutics's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was $-35.15 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-123.06 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Nektar Therapeutics's annualizedROC % for the quarter that ended in Mar. 2026 was -127.88%.
Nektar Therapeutics's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -5,622.56%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Nektar Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -7.40%.
Nektar Therapeutics (LTS:0UNL) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Nektar Therapeutics's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nektar Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nektar Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-123.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics (LTS:0UNL) has a EBIT of $-123.06 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nektar Therapeutics.
Is Nektar Therapeutics' EBIT too high?
Nektar Therapeutics' current EBIT is $-123.06 Mil. Overall, Nektar Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' EBIT compare to PHVS and KOD?
Nektar Therapeutics' EBIT of $-123.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nektar Therapeutics. Nektar Therapeutics's current EBIT is $-123.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (LTS:0UNL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.81, compared to a current price of $61.67 — trading 961.4% above its estimated fair value. The current EBIT is $-123.06 Mil. Nektar Therapeutics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Nektar Therapeutics (LTS:0UNL), the current EBIT is $-123.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nektar Therapeutics (LTS:0UNL) Overvalued in 2026?
Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued.
The current stock price of $61.67 is trading 961.4% above its estimated GF Value™ of $5.81.
GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.
Key valuation signals for LTS:0UNL:
EBIT: $-123.06 Mil
GF Value™: $5.81 vs. price of $61.67 (961.4% above fair value)
No single metric tells the full story. See the LTS:0UNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
49GF Score
Get the complete analysis for LTS:0UNL
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0UNL has been successfully added to your 
